263 related articles for article (PubMed ID: 32447209)
1. Design of integrin α
Lv X; Zhang C; Shuaizhen Q; Yu R; Zheng Y
Biomed Pharmacother; 2020 Aug; 128():110236. PubMed ID: 32447209
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel dual-cyclic RGD peptides for α
Liu J; Cheng X; Tian X; Guan D; Ao J; Wu Z; Huang W; Le Z
Bioorg Med Chem Lett; 2019 Apr; 29(7):896-900. PubMed ID: 30732943
[TBL] [Abstract][Full Text] [Related]
3. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
4. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
Zhang Q; Lu L; Zhang L; Shi K; Cun X; Yang Y; Liu Y; Gao H; He Q
Sci Rep; 2016 Feb; 6():19800. PubMed ID: 26842655
[TBL] [Abstract][Full Text] [Related]
5. Combined integrin α
Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
[TBL] [Abstract][Full Text] [Related]
6. Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain.
Diao Y; Han W; Zhao H; Zhu S; Liu X; Feng X; Gu J; Yao C; Liu S; Sun C; Pan F
J Pept Sci; 2012 Jul; 18(7):476-86. PubMed ID: 22641352
[TBL] [Abstract][Full Text] [Related]
7. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides.
Massaguer A; González-Cantó A; Escribano E; Barrabés S; Artigas G; Moreno V; Marchán V
Dalton Trans; 2015 Jan; 44(1):202-12. PubMed ID: 25369773
[TBL] [Abstract][Full Text] [Related]
8. Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide.
Feni L; Parente S; Robert C; Gazzola S; Arosio D; Piarulli U; Neundorf I
Bioconjug Chem; 2019 Jul; 30(7):2011-2022. PubMed ID: 31243977
[TBL] [Abstract][Full Text] [Related]
9. Design BH3 domain fusion protein as targeting pro-apoptotic self-assembling nanoparticles.
Shuai Z; Zheng Y; Jiang J; Yu R; Zhang C
Biomed Pharmacother; 2021 Sep; 141():111825. PubMed ID: 34153848
[TBL] [Abstract][Full Text] [Related]
10. Integrin αvβ3 targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides.
Liu Y; Mei L; Yu Q; Zhang Q; Gao H; Zhang Z; He Q
Amino Acids; 2015 Dec; 47(12):2533-9. PubMed ID: 26173509
[TBL] [Abstract][Full Text] [Related]
11. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
12. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [
Mohammadi R; Shokri B; Shamshirian D; Zarghi A; Shahhosseini S
Daru; 2020 Jun; 28(1):87-96. PubMed ID: 31845157
[TBL] [Abstract][Full Text] [Related]
14. A Nanosystem of Amphiphilic Oligopeptide-Drug Conjugate Actualizing Both αvβ3 Targeting and Reduction-Triggered Release for Maytansinoid.
Liang Y; Li S; Wang X; He B; He B; Dai W; Zhang H; Wang X; Wang Y; Zhou D; Zhang Q
Theranostics; 2017; 7(13):3306-3318. PubMed ID: 28900511
[TBL] [Abstract][Full Text] [Related]
15. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel.
Danhier F; Vroman B; Lecouturier N; Crokart N; Pourcelle V; Freichels H; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Dec; 140(2):166-73. PubMed ID: 19699245
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of Modified RGD-Based Peptides and Their in vitro Activity.
Hamdan F; Bigdeli Z; Asghari SM; Sadremomtaz A; Balalaie S
ChemMedChem; 2019 Jan; 14(2):282-288. PubMed ID: 30506622
[TBL] [Abstract][Full Text] [Related]
17. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
Temming K; Schiffelers RM; Molema G; Kok RJ
Drug Resist Updat; 2005 Dec; 8(6):381-402. PubMed ID: 16309948
[TBL] [Abstract][Full Text] [Related]
18. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy.
Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S
Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910
[TBL] [Abstract][Full Text] [Related]
19. RGD mimetics γ-AApeptides and methods of use (US 20,140,004,039 A1): a patent evaluation.
Wu H; Jiang J; Xu H; Li Q; Cai J
Expert Opin Ther Pat; 2016; 26(1):131-7. PubMed ID: 26560186
[TBL] [Abstract][Full Text] [Related]
20. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
